-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
DQ8EgL+Gk8nfqFuSLTNCdtWjZUukXMZldu45gUkrzu7Oo4qr/6F+XIXfMMgDNK7z
Gl7KX1PzuYjW1nxa8EZdvA==
UNITED STATES FORM 8-K CURRENT REPORT PURSUANTTO
Date of Report
(Date of earliest event reported) November 3, 2005
(Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation)
(Registrants Telephone Number, Including Area Code) (Former Name or Former Address, if Changed Since Last Report) Check
the appropriate box below if the Form 8-K Filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On November 3, 2005, Becton,
Dickinson and Company (BD) issued a press release announcing its
financial results for the fourth fiscal quarter and for the fiscal year ended
September 30, 2005. A copy of the press release is furnished as Exhibit 99.1
to this report. The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted principles (GAAP), as follows: Revenues.
We present revenue growth rates at constant foreign exchange rates. We
believe that presenting growth rates at constant foreign exchange rates
allows investors to view the underlying operating results of BD and of
its segments without the impact of fluctuations in foreign currency exchange
rates, thereby facilitating comparisons to prior periods. Cost
of Products Sold. We present cost of products
sold, both alone and as a percentage of revenues, after excluding the
impact of share-based compensation expense for the period. Management
presents these adjusted measures in order to assist investors in comparing
BDs cost of products sold for the period to prior periods in which
such expense was not recognized. Gross
Profit/Gross Profit Margin. We present gross profit
and gross profit margin after excluding the impact of share-based compensation
expense for the period. Management presents these adjusted measures in
order to assist investors in comparing BDs gross profit and gross
profit margin for the period to prior periods in which such expense was
not recognized. We
also separately present gross profit and gross profit margin after excluding
the impact of significant charges. Management believes that these adjusted
measures of gross profit and gross profit margin are more indicative of
BDs underlying performance, and also allow investors to better understand
BDs comparative operating performance for the period presented.
Operating
Income. We present BDs operating income,
both alone and as a percentage of revenues, after excluding the impact
of share-based compensation expense for the period. Management presents
these adjusted measures in order to assist investors in comparing BDs
operating income for the period to prior periods in which such expense
was not recognized. We
also separately present these measures after excluding the impact of significant
charges. Management believes that these adjusted measures of operating
income are more indicative of BDs underlying performance, and also
allow investors to better understand BDs comparative operating performance
for the period presented. Income from Continuing Operations. We present operating income from continuing operations, both alone and as a percentage of revenues, after excluding (i) the impact of share-based Net
Income. We present BDs net income, both
alone and as a percentage of revenues, after excluding the impact of significant
charges. Management believes that these adjusted measures of net income
are more indicative of BDs underlying performance, and also allow
investors to better understand BDs comparative operating performance
for the period presented. Earnings
Per Share. We present earnings per share and earnings
per share from continuing operations after excluding the impact of significant
charges. Management believes that this adjusted measure of earnings per
share is more indicative of BDs underlying performance, and also
allow investors to better understand BDs comparative operating performance
for the period presented. Selling
and Administrative Expense. We present selling
and administrative expense, both alone and as a percentage of revenues,
after excluding the impact of share-based compensation expense for the
period. Management presents these adjusted measures in order to assist
investors in comparing BDs selling and administrative expense for
the period to prior periods in which such share-based compensation expense
was not recognized. Research
and Development Expense. We present research and
development expense, both alone and as a percentage of revenues, after
excluding the impact of share-based compensation expense for the period.
Management presents these adjusted measures in order to assist investors
in comparing BDs investment in research and development for the
period to prior periods in which such share-based compensation expense
was not recognized. Income
Taxes/Effective Tax Rate. We present income taxes
and effective tax rate after excluding (i) the impact of share-based compensation
expense for the period, (ii) the impact on taxes of the planned repatriation
of foreign earnings under the provisions of the American Jobs Creation
Act, and (iii) the effects of significant reversals of tax reserves (for
the full 2005 fiscal year) or the effects of changes in tax laws and regulations
and other events that cause the tax rate for the fourth quarter of fiscal
year 2005 to vary from BDs expected effective tax rate for the full
year. Management provides these adjusted measures of income taxes and
effective tax rate in order to facilitate comparisons to prior periods
and to allow investors to reconcile the effective tax rate for the period
being presented with the effective tax rate for the full fiscal year.
BDs management uses each of these non-GAAP measures in its own evaluation of BDs performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis. Non-GAAP
results should not be considered in isolation and are not in accordance with,
or a substitute for, GAAP results. Our non-GAAP results may differ from similar
measures used by other companies, even if similar terms are used to identify
such measures. Although BDs management believes non-GAAP results are useful
in evaluating the performance of its business, its reliance on these measures
is limited since items excluded from such measures may have a material impact
on BDs net income, earnings per share or cash flows calculated in accordance
with GAAP. Therefore, management typically uses non-GAAP results in conjunction
with GAAP results to address these limitations. Investors should also consider
these limitations when evaluating BDs results. BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BDs financial results. Management believes the non-GAAP results provide a reasonable measure of BDs underlying performance before the effects of items that are considered by management to be outside of BDs underlying operational results or that affect period to period comparability. ITEM 8.01 OTHER EVENTS. On
September 12, 2005, Dik Drug Company filed a purported class action lawsuit
against BD in the United States District Court in Newark, New Jersey (2:05-cv-04465-JLL-RJH).
On October 3, 2005, American Sales Company, Inc. filed a purported class action
against BD in the United States District Court in Philadelphia, Pennsylvania
(2:05-cv-05212-CMR). On October 26, 2005, Park Surgical Co. Inc., a New York
corporation, filed a purported class action lawsuit against BD in the United
States District Court in Philadelphia, Pennsylvania (2:05-cv-05678-CMR). The
complaints allege that BD violated federal antitrust laws, resulting in the
charging of higher prices for certain BD products to plaintiffs and other purported
class members. These complaints are similar to the previously reported complaints
filed in March 2005 against BD in the United States District Court in Newark,
New Jersey by Louisiana Wholesale Drug Company, and in September 2005 against
BD in the United States District Court in Philadelphia, Pennsylvania by SAJ
Distributors, Inc., in that they are brought on behalf of direct purchasers
such as distributors. The plaintiffs seek money damages in as yet undisclosed
amounts. The
actions brought by Louisiana Wholesale Drug Company and Dik Drug Company in
New Jersey have been consolidated and are now captioned In re Hypodermic
Products Antitrust Litigation. In addition, BD has made a motion before
the Judicial Panel on Multidistrict Litigation to transfer the actions brought
by Louisiana Wholesale Drug Company, Dik Drug Company, American Sales Company,
Inc., and SAJ Distributors, Inc., along with the previously reported action
brought by Jabos Pharmacy, Inc. against BD in the United States District
Court in Greeneville, Tennessee, for coordinated or consolidated pre-trial proceedings.
BD expects that the action brought by Park Surgical Co. Inc. will be added to
BDs motion to the Judicial Panel on Multidistrict Litigation in the near
future. BD
believes it has meritorious defenses to these claims and intends to defend these
lawsuits vigorously. ITEM 9.01 FINANCIAL STATEMENTS
AND EXHIBITS. SIGNATURES Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November
3, 2005 INDEX TO EXHIBITS 1
Becton Drive Franklin
Lakes, NJ 07417 www.bd.com
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT
OF 1934
BECTON, DICKINSON AND
COMPANY
New Jersey
001-4802
22-0760120
1 Becton Drive, Franklin
Lakes, New Jersey
07417-1880
(201) 847-6800
N/A
compensation
expense for the period, (ii) the impact on taxes of the planned repatriation
of foreign earnings under the provisions of the American Jobs Creation Act,
and (iii) the effects of significant reversals of tax reserves (for the
full 2005 fiscal year) or the effects of changes in tax laws and regulations
(including without limitation, rate changes) and other events that cause
the tax rate for the fourth quarter of fiscal year 2005 to vary from BDs
expected effective tax rate for the full year. Management eliminates the
effect of share-based compensation and the repatriation of foreign earnings
in these instances in order to improve comparability to prior periods in
which such expenses were not recognized. In addition, significant reversals
of tax reserves and the items mentioned above that affect our periodic effective
tax rate cause fluctuations in BDs operating income from continuing
operations from period to period that management believes are unrelated
to BDs underlying operating performance. Accordingly, management believes
that providing the impact of such effects allows investors to better understand
BDs comparative operating performance for the period presented.
We also separately
present these measures after excluding the impact of significant charges.
Managment believes these adjusted measures of income from continuing operations
are more indicative of BD's underlying performance, and also allow investors
to better understand BDs comparative operating performance for the
period presented.
We also
present earnings per share and earnings per share from continuing operations
after excluding (i) the impact of share-based compensation expense for the
period, (ii) the impact on taxes of the planned repatriation of foreign
earnings under the provisions of the American Jobs Creation Act, and (iii)
the effects of significant reversals of tax reserves, (for the full 2005
fiscal year) or the effects of changes in tax laws and regulations and other
events that cause the tax rate for the fourth quarter of fiscal year 2005
to vary from BDs expected effective tax rate for the full year. Management
eliminates the effect of share-based compensation and the repatriation of
foreign earnings in these instances in order to improve comparability to
prior periods in which such expenses were not recognized. In addition, significant
reversals of tax reserves and the items mentioned above that effect our
periodic effective tax rate cause fluctuations in BDs operating income
from continuing operations from period to period that management believes
are unrelated to BDs underlying operating performance. Accordingly,
management believes that providing the impact of such effects allows investors
to better understand BDs comparative operating performance for the
period presented.
Exhibits. —
Exhibit 99.1 Press
release dated November 3, 2005, which is furnished pursuant to Item 2.02.
BECTON, DICKINSON AND COMPANY
(Registrant)
By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy
Number
99.1
Press
release dated November 3, 2005, which is furnished pursuant to Item 2.02.
News Release |
Contact:
Patricia A. Spinella, Investor Relations 201-847-5453
Colleen T. White, Corporate Communications 201-847-5369
BD ANNOUNCES RESULTS FOR FOURTH FISCAL QUARTER AND FULL YEAR
|
|
Fourth-quarter and full-year revenues each increased 10%; annual revenues were $5.4 billion |
|
|
Fourth-quarter and full-year earnings per share from continuing operations, excluding specified items and share-based compensation expense, increased 19% to 83 cents and 20% to $3.07, respectively |
|
|
The Company plans to repatriate $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act |
Franklin Lakes, NJ (November 3, 2005) BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of $1.379 billion for the fourth fiscal quarter ended September 30, 2005, representing an increase of 10 percent over the prior year period. This quarters growth rate includes an estimated 2 percent benefit from foreign currency translation. Revenue growth in all segments benefited from foreign currency translation, driven primarily by favorable exchange rates in Latin America, Asia Pacific, and Canada.
Our excellent results this year were driven, in particular, by our strong international performance, new product revenue growth, and significant margin improvement, said Edward J. Ludwig, Chairman, President and Chief Executive Officer. Our Asia Pacific/Japan, Canada, Europe, and Latin American regions contributed double-digit revenue growth and the combination of higher margin products and increased operating effectiveness drove margin expansion. Performance such as this will allow us to continue to increase the pace of our R&D spending while also targeting double-digit earnings growth.
Our strong fourth quarter provides a solid foundation for fiscal 2006, added Mr. Ludwig. We feel confident in our expectation that earnings will grow by approximately 10 percent. On a performance basis, this equates to about 14 percent, excluding the expected negative impact of foreign currency translation.
Analyses of Fourth Quarter and Full Fiscal Year 2005 and 2004 Earnings
The
following analyses of diluted earnings per share from continuing operations
for the fourth quarter and full fiscal year 2005 and 2004 identify specified
items and share-based compensation expense that affect comparability of results
between periods.
(Table 1) | Three
Months Ended September 30, |
Twelve-month
Period Ended September 30, |
|||||||||||||||||||||||
FY2005 | FY2004 | % Incr.(Decr.) | FY2005 | FY2004 | % Incr.(Decr.) | ||||||||||||||||||||
Reported Diluted EPS | $ | 0.58 | $ | 0.26 | $ | 2.77 | $ | 1.77 | |||||||||||||||||
Diluted EPS from Discontinued Operations: | |||||||||||||||||||||||||
Income from Clontech | | | (0.01 | ) | | ||||||||||||||||||||
Gain on Sale of Clontech | (0.11 | ) | | (0.11 | ) | | |||||||||||||||||||
Write-down of Clontech Net Assets | | 0.44 | | 0.44 | |||||||||||||||||||||
Rounding | | | 0.01 | | |||||||||||||||||||||
(0.11 | ) | 0.44 | (0.11 | ) | 0.44 | ||||||||||||||||||||
Diluted EPS from Continuing Operations | 0.47 | 0.70 | -33% | 2.66 | 2.21 | 20 | % | ||||||||||||||||||
Specified Items: | |||||||||||||||||||||||||
Tax Examinations(1) | | | (0.04 | ) | | ||||||||||||||||||||
Tax Rate Impact(2) | 0.02 | | | | |||||||||||||||||||||
Repatriation Tax Charge(3) | 0.27 | | 0.27 | | |||||||||||||||||||||
BGM Charges(4) | | | | 0.11 | |||||||||||||||||||||
Litigation Settlement(5) | | | | 0.24 | |||||||||||||||||||||
Rounding | | | (0.01 | ) | | ||||||||||||||||||||
0.29 | | 0.22 | 0.35 | ||||||||||||||||||||||
Diluted EPS from Continuing Operations Excluding Specified Items |
0.76 | 0.70 | 2.88 | 2.56 | |||||||||||||||||||||
Share-based Compensation Expense(6) | 0.07 | | 0.19 | | |||||||||||||||||||||
Diluted EPS from Continuing Operations Excluding Specified Items and Share-based Compensation Expense |
$ | 0.83 | $ | 0.70 | 19 | % | $ | 3.07 | $ | 2.56 | 20 | % | |||||||||||||
(1) Included in diluted earnings per share from continuing operations for the fiscal year ended September 30, 2005 is a benefit of approximately 4 cents per diluted share due to the reversal of tax reserves in connection with the conclusion of tax examinations in four non-U.S. jurisdictions that occurred in the first quarter.
(2) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the tax rate to vary from the expected effective tax rate for the year. The effective tax rate for the year, without taking into account the tax impact of the items described in notes (1), (3) and (6) herein, is 25.5%.
(3) Included in diluted earnings per share from continuing operations for the fourth quarter of fiscal 2005 is 27 cents per diluted share substantially related to the impact on taxes of the planned repatriation of $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act.
(4) Included in fiscal 2004 diluted earnings per share from continuing operations is a first quarter charge of 11 cents per diluted share related to the voluntary recall and write-off of certain blood glucose strip inventory and other actions taken with respect to our blood glucose monitoring products.
(5) Included in fiscal 2004 diluted earnings per share from continuing operations is a third quarter charge of 24 cents per diluted share related to a litigation settlement.
(6) Represents the effect on diluted earnings per share from continuing operations relating to share-based compensation expense in accordance with the first quarter adoption of FASB Statement No. 123 (revised), Share-Based Payment.
Based on the foregoing analyses, diluted earnings per share from continuing operations for the fourth fiscal quarter of 2005, excluding specified items and share-based compensation expense, of 83 cents increased by 19 percent over diluted earnings per share from continuing operations of 70 cents for the fourth fiscal quarter of 2004. For the year, diluted earnings per share from continuing operations, excluding specified items and share-based compensation expense, of $3.07 increased by 20 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.56 for fiscal 2004.
Reported diluted earnings per share for the fourth quarter of fiscal 2005 were 58 cents, including a 27 cents per diluted share tax charge that relates substantially to the Companys planned repatriation of $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act, and a gain of 11 cents per diluted share from discontinued operations resulting from the sale of Clontech on August 31, 2005.
Reported diluted earnings per share for the fourth quarter of fiscal 2004 were 26 cents, reflecting a loss of 44 cents per share from discontinued operations and diluted earnings per share from continuing operations of 70 cents.
For the fiscal year ended September 30, 2005, reported revenues were $5.415 billion, representing a 10 percent increase from the prior year, including an estimated 3 percent benefit from foreign currency translation, which was based on favorable exchange rates in all regions. Reported diluted earnings per share for the fiscal year ended September 30, 2005 were $2.77, including the previously noted fourth quarter tax charge of 27 cents per share and a gain of 11 cents per share from discontinued operations resulting from the sale of Clontech.
For fiscal year 2004, reported diluted earnings per share were $1.77, which reflected diluted earnings per share of $2.21 from continuing operations, and a loss of 44 cents per share from discontinued operations. Included in the results of continuing operations for the year were a first quarter charge of 11 cents per share related to our blood glucose monitoring products and a third quarter charge of 24 cents per share related to a litigation settlement.
Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $762 million, representing an increase of 11 percent from the prior year period. Contributing to the growth of the segment were strong sales in the Diabetes Care unit. Also contributing to growth were solid sales in the Medical Surgical Systems and Pharmaceutical Systems units. U.S. sales of safety-engineered products totaled $130 million, compared with $122 million in the prior years quarter. Included in BD Medical revenues for the quarter were international sales of safety-engineered products of $21 million, compared with $16 million in the prior years quarter.
For the full fiscal year ended September 30, 2005, total BD Medical segment revenues of $2.958 billion increased by 10 percent from the prior year. U.S. sales of safety-engineered products totaled $490 million, compared with $459 million in the prior year. International sales of safety-engineered products totaled $81 million, compared with $63 million in the prior year.
In the BD Diagnostics segment, worldwide revenues for the quarter were $403 million, representing an increase of 8 percent from the prior year period. The Diagnostic Systems unit of the segment reported revenue growth of 9 percent, due primarily to increased worldwide sales of its newer instrument platforms, BD Phoenix and BD ProbeTec ET. The Preanalytical Systems unit of the segment reported revenue growth of 7 percent. U.S. sales of safety-engineered products, benefiting from BD Vacutainer® Push Button Blood Collection Set activity, totaled $94 million, compared with $85 million in the prior years quarter. Included in Preanalytical Systems revenues for the quarter were international sales of safety-engineered products of $49 million, compared with $39 million in the prior years quarter.
For the full fiscal year ended September 30, 2005, total BD Diagnostics segment revenues of $1.657 billion increased by 8 percent from the prior year. U.S. sales of safety-engineered products totaled $352 million, compared with $317 million in the prior year. International sales of safety-engineered products totaled $192 million, compared with $140 million in the prior year.
In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were $214 million, representing an increase of 12 percent from the prior year period. Research instrument and reagent sales continued to be the primary growth contributors, driven by increased demand for research analyzers. As in the previous two quarters, increased sales of Discovery Labware products also contributed to revenue growth.
For the full fiscal year ended September 30, 2005, total BD Biosciences segment revenues of $800 million increased by 11 percent from the prior year, representing continued strong sales of flow cytometry instruments and reagents.
Geographic Results
Fourth quarter revenues in the U.S. of $687 million represented an increase of 9 percent over the prior year period. Revenues outside the U.S. of $692 million represented an increase of 11 percent over the prior year period, including an estimated 3 percent benefit from foreign currency translation.
For the full fiscal year ended September 30, 2005, revenues in the U.S. of $2.591 billion represented an increase of 6 percent over the prior year. Revenues outside of the U.S. of $2.824 billion represented an increase of 13 percent over the prior year, including an estimated 5 percent benefit from foreign currency translation.
Fiscal 2006 Outlook for Full Year and First Quarter
The Company estimates that diluted earnings per share from continuing operations for the fiscal year 2006 will increase approximately 10 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.88 for the fiscal year 2005.
The Company also estimates that diluted earnings per share from continuing operations for the first fiscal quarter of 2006 will increase approximately 10 percent over diluted earnings per share from continuing operations, excluding specified items, of 68 cents for the first fiscal quarter of 2005.
The following analyses of estimated diluted earnings per share from continuing operations for the first fiscal quarter and full year identify specified items that affect the comparability of results between periods.
(Table 2) | Three
Months Ended December 31, |
Twelve
months Ended September 30, |
|||||||||||||||||||||||
FY2006 | FY2005 | % Incr. | FY2006 | FY2005 | % Incr. | ||||||||||||||||||||
(Estimated) |
(Estimated) |
||||||||||||||||||||||||
Diluted EPS from Continuing Operations | $ | 0.74-$0.75 | $ | 0.74 | 0%-1% | $ | 3.15-$3.19 | $ | 2.66 | 18%-20% | |||||||||||||||
Specified Items: | |||||||||||||||||||||||||
Tax Examinations(1) | | (0.04 | ) | | (0.04 | ) | |||||||||||||||||||
Tax Rate Impact(2) | | (0.02 | ) | | | ||||||||||||||||||||
Repatriation Tax Charge(3) | | | | 0.27 | |||||||||||||||||||||
Rounding | | | | (0.01 | ) | ||||||||||||||||||||
| (0.06 | ) | | 0.22 | |||||||||||||||||||||
Diluted EPS from Continuing Operations Excluding Specified Items | $ | 0.74-$0.75 | $ | 0.68 | 9%-10% | $ | 3.15-$3.19 | $ | 2.88 | 9%-11% |
(1) Represents the effect on estimated diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.
(2) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the tax rate to vary from the expected effective tax rate for fiscal 2005.
(3) Included in diluted earnings per share from continuing operations for the fourth quarter of fiscal 2005 is 27 cents per diluted share substantially related to the impact on taxes of the planned repatriation of $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act.
Conference Call Information
A conference call regarding BDs fourth fiscal quarter and full year results and its expectations for the first fiscal quarter and full fiscal year 2006 will be broadcast live on BDs website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, November 3, 2005. The conference call will be available for replay on BDs website, www.bd.com/investors, or at 1-866-347-5807 (domestic) and 1-203-369-0023 (international) through the close of business on November 10, 2005.
This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. To learn more about BD, please visit www.bd.com.
***
This press release, including the section entitled Fiscal 2006 Outlook for Full Year and First Quarter, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BDs performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in
product introductions; changes in regional, national or foreign economic conditions; increases in energy costs and their effect on, among other things, the cost of producing BDs products; fluctuations in costs and availability of raw materials and in BDs ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BDs filings with the Securities and Exchange Commission); changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BDs filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
|
|
Three Months Ended September 30, |
|||||||
|
|
2005 |
|
2004 |
|
% Change |
|
||
|
|
|
|
|
|
|
|
|
|
REVENUES |
|
$ |
1,379,476 |
|
$ |
1,253,278 |
|
10.1 |
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold |
|
|
662,746 |
(1) |
|
620,978 |
|
6.7 |
|
Selling and administrative |
|
|
376,510 |
(1) |
|
320,269 |
|
17.6 |
|
Research and development |
|
|
76,552 |
(1) |
|
58,708 |
|
30.4 |
|
TOTAL OPERATING COSTS AND EXPENSES |
|
|
1,115,808 |
|
|
999,955 |
|
11.6 |
|
|
|
|
|
|
|
|
|
|
|
OPERATING INCOME |
|
|
263,668 |
|
|
253,323 |
|
4.1 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
(2,013 |
) |
|
(8,592 |
) |
(76.6 |
) |
Other expense, net |
|
|
(977 |
) |
|
(161 |
) |
NM |
|
|
|
|
|
|
|
|
|
|
|
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES |
|
|
260,678 |
|
|
244,570 |
|
6.6 |
|
|
|
|
|
|
|
|
|
|
|
Income tax provision |
|
|
139,103 |
|
|
61,236 |
|
NM |
|
|
|
|
|
|
|
|
|
|
|
INCOME FROM CONTINUING OPERATIONS |
|
|
121,575 |
|
|
183,334 |
|
(33.7 |
) |
|
|
|
|
|
|
|
|
|
|
INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX BENEFIT OF $15,986 IN 2005 AND $8,349 IN 2004, RESPECTIVELY |
|
|
27,519 |
|
|
(115,890 |
) |
NM |
|
|
|
|
|
|
|
|
|
|
|
NET INCOME |
|
$ |
149,094 |
|
$ |
67,444 |
|
NM |
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
0.49 |
|
$ |
0.73 |
|
(32.9 |
) |
Income (loss) from discontinued operations |
|
$ |
0.11 |
|
$ |
(0.46 |
) |
NM |
|
Net income |
|
$ |
0.60 |
|
$ |
0.27 |
|
NM |
|
|
|
|
|
|
|
|
|
|
|
Diluted: |
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
0.47 |
|
$ |
0.70 |
|
(32.9 |
) |
Income (loss) from discontinued operations |
|
$ |
0.11 |
|
$ |
(0.44 |
) |
NM |
|
Net income |
|
$ |
0.58 |
|
$ |
0.26 |
|
NM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AVERAGE SHARES OUTSTANDING |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
249,236 |
|
|
250,202 |
|
|
|
Diluted |
|
|
256,878 |
|
|
261,334 |
|
|
|
NM - Not Meaningful
(1) |
Includes share-based compensation expense in accordance with the first quarter adoption of SFAS No. 123 (revised), Share-Based Payment. |
Page 1
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended September 30,
(Unaudited; Amounts in thousands, except per-share data)
|
|
2005 |
|
|
|
|
|
||||||||||||
|
|
As
|
|
SFAS# 123(revised) |
|
Tax |
|
Repatriation |
|
Excluding |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold |
|
$ |
662,746 |
|
$ |
(3,456 |
) |
|
$ |
|
|
|
$ |
|
|
|
$ |
659,290 |
|
as a % of revenues |
|
|
48.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
716,730 |
|
|
3,456 |
|
|
|
|
|
|
|
|
|
|
|
720,186 |
|
as a % of revenues |
|
|
52.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52.2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and administrative |
|
|
376,510 |
|
|
(19,570 |
) |
|
|
|
|
|
|
|
|
|
|
356,940 |
|
as a % of revenues |
|
|
27.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
76,552 |
|
|
(2,149 |
) |
|
|
|
|
|
|
|
|
|
|
74,403 |
|
as a % of revenues |
|
|
5.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
|
263,668 |
|
|
25,175 |
|
|
|
|
|
|
|
|
|
|
|
288,843 |
|
as a % of revenues |
|
|
19.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
139,103 |
|
|
7,610 |
|
|
|
(4,181 |
) |
|
|
(69,638 |
) |
|
|
72,894 |
|
effective tax rate |
|
|
53.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
121,575 |
|
|
17,565 |
|
|
|
4,181 |
|
|
|
69,638 |
|
|
|
212,959 |
|
as a % of revenues |
|
|
8.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
0.47 |
|
$ |
0.07 |
|
|
$ |
0.02 |
|
|
$ |
0.27 |
|
|
$ |
0.83 |
|
Income from discontinued operations |
|
$ |
0.11 |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
0.11 |
|
Diluted earnings per share |
|
$ |
0.58 |
|
$ |
0.07 |
|
|
$ |
0.02 |
|
|
$ |
0.27 |
|
|
$ |
0.94 |
|
(1) |
Relates to the first quarter adoption of SFAS No. 123 (revised), "Share-Based Payment". Fiscal 2004 amounts have not been restated. |
(2) |
Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the tax rate to vary from the expected effective tax rate for the year. |
(3) |
Relates substantially to the planned repatriation of $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act. |
Page 2
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
|
|
Twelve Months Ended September 30, |
|||||||
|
|
2005 |
|
2004 |
|
% Change |
|
||
REVENUES |
|
$ |
5,414,681 |
|
$ |
4,934,745 |
|
9.7 |
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold |
|
|
2,662,029 |
(1) |
|
2,500,362 |
(2) |
6.5 |
|
Selling and administrative |
|
|
1,449,856 |
(1) |
|
1,311,467 |
|
10.6 |
|
Research and development |
|
|
271,626 |
(1) |
|
235,649 |
|
15.3 |
|
Litigation settlement |
|
|
|
|
|
100,000 |
|
NM |
|
TOTAL OPERATING COSTS AND EXPENSES |
|
|
4,383,511 |
|
|
4,147,478 |
|
5.7 |
|
OPERATING INCOME |
|
|
1,031,170 |
|
|
787,267 |
|
31.0 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
(19,252 |
) |
|
(29,607 |
) |
(35.0 |
) |
Other (expense) income, net |
|
|
(7,064 |
) |
|
(4,792 |
) |
47.4 |
|
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES |
|
|
1,004,854 |
|
|
752,868 |
|
33.5 |
|
|
|
|
|
|
|
|
|
|
|
Income tax provision |
|
|
312,571 |
|
|
170,364 |
|
83.5 |
|
INCOME FROM CONTINUING OPERATIONS |
|
|
692,283 |
|
|
582,504 |
|
18.8 |
|
|
|
|
|
|
|
|
|
|
|
INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX BENEFIT OF $14,439 IN 2005 AND $7,961 IN 2004, RESPECTIVELY |
|
|
29,980 |
|
|
(115,102 |
) |
NM |
|
|
|
|
|
|
|
|
|
|
|
NET INCOME |
|
$ |
722,263 |
|
$ |
467,402 |
|
54.5 |
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
2.75 |
|
$ |
2.30 |
|
19.6 |
|
Income (loss) from discontinued operations |
|
$ |
0.12 |
|
$ |
(0.46 |
) |
NM |
|
Net income (3) |
|
$ |
2.87 |
|
$ |
1.85 |
|
55.1 |
|
|
|
|
|
|
|
|
|
|
|
Diluted: |
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
2.66 |
|
$ |
2.21 |
|
20.4 |
|
Income (loss) from discontinued operations |
|
$ |
0.11 |
|
$ |
(0.44 |
) |
NM |
|
Net income |
|
$ |
2.77 |
|
$ |
1.77 |
|
56.5 |
|
|
|
|
|
|
|
|
|
|
|
AVERAGE SHARES OUTSTANDING |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
251,429 |
|
|
252,011 |
|
|
|
Diluted |
|
|
260,712 |
|
|
263,337 |
|
|
|
NM - Not Meaningful
(1) |
Includes share-based compensation expense in accordance with the first quarter adoption of SFAS No. 123 (revised), "Share-Based Payment". |
(2) |
Includes a $45,024 charge associated with blood glucose monitoring (BGM) products. |
(3) |
Total per share amounts may not add due to rounding. |
Page 3
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands, except per-share data)
|
|
2005 |
|
|
|
|
|
||||||||||||
|
|
As
|
|
SFAS# 123(revised) |
|
Tax |
|
Repatriation |
|
Excluding |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products sold |
|
$ |
2,662,029 |
|
$ |
(9,749 |
) |
|
$ |
|
|
|
$ |
|
|
|
$ |
2,652,280 |
|
as a % of revenues |
|
|
49.2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
2,752,652 |
|
|
9,749 |
|
|
|
|
|
|
|
|
|
|
|
2,762,401 |
|
as a % of revenues |
|
|
50.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
51.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and administrative |
|
|
1,449,856 |
|
|
(54,454 |
) |
|
|
|
|
|
|
|
|
|
|
1,395,402 |
|
as a % of revenues |
|
|
26.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
271,626 |
|
|
(5,996 |
) |
|
|
|
|
|
|
|
|
|
|
265,630 |
|
as a % of revenues |
|
|
5.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
|
1,031,170 |
|
|
70,199 |
|
|
|
|
|
|
|
|
|
|
|
1,101,369 |
|
as a % of revenues |
|
|
19.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
312,571 |
|
|
19,941 |
|
|
|
11,265 |
|
|
|
(69,638 |
) |
|
|
274,139 |
|
effective tax rate |
|
|
31.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
692,283 |
|
|
50,258 |
|
|
|
(11,265 |
) |
|
|
69,638 |
|
|
|
800,914 |
|
as a % of revenues |
|
|
12.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations (4) |
|
$ |
2.66 |
|
$ |
0.19 |
|
|
$ |
(0.04 |
) |
|
$ |
0.27 |
|
|
$ |
3.07 |
|
Income from discontinued operations |
|
$ |
0.11 |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
0.11 |
|
Diluted earnings per share |
|
$ |
2.77 |
|
$ |
0.19 |
|
|
$ |
(0.04 |
) |
|
$ |
0.27 |
|
|
$ |
3.19 |
|
(1) |
Relates to the first quarter adoption of SFAS No. 123 (revised), Share-Based Payment. Fiscal 2004 amounts have not been restated. |
(2) |
Relates to the reversal of tax reserves in connection with the conclusion of tax examinations in four non-U.S. jurisdictions that occurred in the first quarter. |
(3) |
Relates substantially to the planned repatriation of $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act. |
(4) |
Total per share amounts may not add due to rounding. |
|
|
2004 |
|||||||||||
|
|
As |
|
BGM |
|
Litigation |
|
Excluding |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
|
$ |
2,434,383 |
|
$ |
45,024 |
|
$ |
|
|
$ |
2,479,407 |
|
as a % of revenues |
|
|
49.3% |
|
|
|
|
|
|
|
|
50.2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
|
787,267 |
|
|
45,024 |
|
|
100,000 |
|
|
932,291 |
|
as a % of revenues |
|
|
16.0% |
|
|
|
|
|
|
|
|
18.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
|
582,504 |
|
|
27,915 |
|
|
63,000 |
|
|
673,419 |
|
as a % of revenues |
|
|
11.8% |
|
|
|
|
|
|
|
|
13.6% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
2.21 |
|
$ |
0.11 |
|
$ |
0.24 |
|
$ |
2.56 |
|
Loss from discontinued operations |
|
$ |
(0.44 |
) |
$ |
|
|
$ |
|
|
$ |
(0.44 |
) |
Diluted earnings per share |
|
$ |
1.77 |
|
$ |
0.11 |
|
$ |
0.24 |
|
$ |
2.12 |
|
(5) |
Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products. |
(6) |
Relates to the fiscal 2004 charge associated with a litigation settlement. |
Page 4
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
|
|
Three Months Ended September 30, |
|||||||
|
|
2005 |
|
2004 |
|
% Change |
|
||
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
368,752 |
|
$ |
334,189 |
|
10.3 |
|
International |
|
|
393,631 |
|
|
353,822 |
|
11.3 |
|
TOTAL |
|
$ |
762,383 |
|
$ |
688,011 |
|
10.8 |
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
218,768 |
|
$ |
207,979 |
|
5.2 |
|
International |
|
|
184,001 |
|
|
165,645 |
|
11.1 |
|
TOTAL |
|
$ |
402,769 |
|
$ |
373,624 |
|
7.8 |
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
99,623 |
|
$ |
89,157 |
|
11.7 |
|
International |
|
|
114,701 |
|
|
102,486 |
|
11.9 |
|
TOTAL |
|
$ |
214,324 |
|
$ |
191,643 |
|
11.8 |
|
|
|
|
|
|
|
|
|
|
|
TOTAL REVENUES |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
687,143 |
|
$ |
631,325 |
|
8.8 |
|
International |
|
|
692,333 |
|
|
621,953 |
|
11.3 |
|
TOTAL |
|
$ |
1,379,476 |
|
$ |
1,253,278 |
|
10.1 |
|
Page 5
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
|
|
Twelve Months Ended September 30, |
|||||||
|
|
2005 |
|
2004 |
|
% Change |
|
||
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
1,366,688 |
|
$ |
1,274,936 |
|
7.2 |
|
International |
|
|
1,591,400 |
|
|
1,405,229 |
|
13.2 |
|
TOTAL |
|
$ |
2,958,088 |
|
$ |
2,680,165 |
|
10.4 |
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
869,187 |
|
$ |
839,157 |
|
3.6 |
|
International |
|
|
787,877 |
|
|
692,482 |
|
13.8 |
|
TOTAL |
|
$ |
1,657,064 |
|
$ |
1,531,639 |
|
8.2 |
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
355,076 |
|
$ |
321,796 |
|
10.3 |
|
International |
|
|
444,453 |
|
|
401,145 |
|
10.8 |
|
TOTAL |
|
$ |
799,529 |
|
$ |
722,941 |
|
10.6 |
|
|
|
|
|
|
|
|
|
|
|
TOTAL REVENUES |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
2,590,951 |
|
$ |
2,435,889 |
|
6.4 |
|
International |
|
|
2,823,730 |
|
|
2,498,856 |
|
13.0 |
|
TOTAL |
|
$ |
5,414,681 |
|
$ |
4,934,745 |
|
9.7 |
|
Page 6
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)
|
|
United States |
|
||||||
|
|
2005 |
|
2004 |
|
% Change |
|
||
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
Medical Surgical Systems |
|
$ |
224,809 |
|
$ |
208,185 |
|
8.0 |
|
Diabetes Care |
|
|
111,160 |
|
|
91,397 |
|
21.6 |
|
Pharmaceutical Systems |
|
|
27,273 |
|
|
29,014 |
|
(6.0 |
) |
Ophthalmic Systems |
|
|
5,510 |
|
|
5,593 |
|
(1.5 |
) |
TOTAL |
|
$ |
368,752 |
|
$ |
334,189 |
|
10.3 |
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
Preanalytical Systems |
|
$ |
120,843 |
|
$ |
117,624 |
|
2.7 |
|
Diagnostic Systems |
|
|
97,925 |
|
|
90,355 |
|
8.4 |
|
TOTAL |
|
$ |
218,768 |
|
$ |
207,979 |
|
5.2 |
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
Discovery Labware |
|
$ |
30,262 |
|
$ |
26,588 |
|
13.8 |
|
Immunocytometry Systems |
|
|
50,242 |
|
|
43,973 |
|
14.3 |
|
Pharmingen |
|
|
19,119 |
|
|
18,596 |
|
2.8 |
|
TOTAL |
|
$ |
99,623 |
|
$ |
89,157 |
|
11.7 |
|
|
|
|
|
|
|
|
|
|
|
TOTAL UNITED STATES |
|
$ |
687,143 |
|
$ |
631,325 |
|
8.8 |
|
Page 7
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
|
|
International |
|
||||||||||
|
|
|
|
|
|
|
|
% Change |
|
|
|
||
|
|
2005 |
|
2004 |
|
Reported |
|
FX Neutral |
|
FX Impact |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical Surgical Systems |
|
$ |
203,991 |
|
$ |
184,984 |
|
10.3 |
|
4.5 |
|
5.8 |
|
Diabetes Care |
|
|
70,671 |
|
|
63,707 |
|
10.9 |
|
6.7 |
|
4.2 |
|
Pharmaceutical Systems |
|
|
109,505 |
|
|
96,621 |
|
13.3 |
|
11.7 |
|
1.6 |
|
Ophthalmic Systems |
|
|
9,464 |
|
|
8,510 |
|
11.2 |
|
9.9 |
|
1.3 |
|
TOTAL |
|
$ |
393,631 |
|
$ |
353,822 |
|
11.3 |
|
7.0 |
|
4.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preanalytical Systems |
|
$ |
97,806 |
|
$ |
87,504 |
|
11.8 |
|
8.2 |
|
3.6 |
|
Diagnostic Systems |
|
|
86,195 |
|
|
78,141 |
|
10.3 |
|
7.6 |
|
2.7 |
|
TOTAL |
|
$ |
184,001 |
|
$ |
165,645 |
|
11.1 |
|
7.9 |
|
3.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Discovery Labware |
|
$ |
23,835 |
|
$ |
22,366 |
|
6.6 |
|
4.4 |
|
2.2 |
|
Immunocytometry Systems |
|
|
77,428 |
|
|
65,631 |
|
18.0 |
|
16.4 |
|
1.6 |
|
Pharmingen |
|
|
13,438 |
|
|
14,489 |
|
(7.3 |
) |
(7.6 |
) |
0.3 |
|
TOTAL |
|
$ |
114,701 |
|
$ |
102,486 |
|
11.9 |
|
10.4 |
|
1.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL INTERNATIONAL |
|
$ |
692,333 |
|
$ |
621,953 |
|
11.3 |
|
7.8 |
|
3.5 |
|
Page 8
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
|
|
Total |
|
||||||||||
|
|
|
|
|
|
% Change |
|
||||||
|
|
2005 |
|
2004 |
|
Reported |
|
FX Neutral |
|
FX Impact |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical Surgical Systems |
|
$ |
428,800 |
|
$ |
393,169 |
|
9.1 |
|
6.3 |
|
2.8 |
|
Diabetes Care |
|
|
181,831 |
|
|
155,104 |
|
17.2 |
|
15.5 |
|
1.7 |
|
Pharmaceutical Systems |
|
|
136,778 |
|
|
125,635 |
|
8.9 |
|
7.6 |
|
1.3 |
|
Ophthalmic Systems |
|
|
14,974 |
|
|
14,103 |
|
6.2 |
|
5.4 |
|
0.8 |
|
TOTAL |
|
$ |
762,383 |
|
$ |
688,011 |
|
10.8 |
|
8.6 |
|
2.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preanalytical Systems |
|
$ |
218,649 |
|
$ |
205,128 |
|
6.6 |
|
5.1 |
|
1.5 |
|
Diagnostic Systems |
|
|
184,120 |
|
|
168,496 |
|
9.3 |
|
8.0 |
|
1.3 |
|
TOTAL |
|
$ |
402,769 |
|
$ |
373,624 |
|
7.8 |
|
6.4 |
|
1.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Discovery Labware |
|
$ |
54,097 |
|
$ |
48,954 |
|
10.5 |
|
9.5 |
|
1.0 |
|
Immunocytometry Systems |
|
|
127,670 |
|
|
109,604 |
|
16.5 |
|
15.6 |
|
0.9 |
|
Pharmingen |
|
|
32,557 |
|
|
33,085 |
|
(1.6 |
) |
(1.8 |
) |
0.2 |
|
TOTAL |
|
$ |
214,324 |
|
$ |
191,643 |
|
11.8 |
|
11.0 |
|
0.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL REVENUES |
|
$ |
1,379,476 |
|
$ |
1,253,278 |
|
10.1 |
|
8.3 |
|
1.8 |
|
Page 9
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)
|
|
United States |
|
||||||
|
|
2005 |
|
2004 |
|
% Change |
|
||
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
Medical Surgical Systems |
|
$ |
852,804 |
|
$ |
803,529 |
|
6.1 |
|
Diabetes Care |
|
|
391,109 |
|
|
340,669 |
|
14.8 |
|
Pharmaceutical Systems |
|
|
101,128 |
|
|
108,027 |
|
(6.4 |
) |
Ophthalmic Systems |
|
|
21,647 |
|
|
22,711 |
|
(4.7 |
) |
TOTAL |
|
$ |
1,366,688 |
|
$ |
1,274,936 |
|
7.2 |
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
Preanalytical Systems |
|
$ |
462,939 |
|
$ |
447,020 |
|
3.6 |
|
Diagnostic Systems |
|
|
406,248 |
|
|
392,137 |
|
3.6 |
|
TOTAL |
|
$ |
869,187 |
|
$ |
839,157 |
|
3.6 |
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
Discovery Labware |
|
$ |
110,419 |
|
$ |
100,821 |
|
9.5 |
|
Immunocytometry Systems |
|
|
169,895 |
|
|
148,741 |
|
14.2 |
|
Pharmingen |
|
|
74,762 |
|
|
72,234 |
|
3.5 |
|
TOTAL |
|
$ |
355,076 |
|
$ |
321,796 |
|
10.3 |
|
|
|
|
|
|
|
|
|
|
|
TOTAL UNITED STATES |
|
$ |
2,590,951 |
|
$ |
2,435,889 |
|
6.4 |
|
Page 10
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
|
|
International |
|||||||||||
|
|
|
|
|
|
|
|
% Change |
|
|
|
||
|
|
2005 |
|
2004 |
|
Reported |
|
FX Neutral |
|
FX Impact |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical Surgical Systems |
|
$ |
808,346 |
|
$ |
737,194 |
|
9.7 |
|
4.1 |
|
5.6 |
|
Diabetes Care |
|
|
282,911 |
|
|
245,521 |
|
15.2 |
|
9.4 |
|
5.8 |
|
Pharmaceutical Systems |
|
|
462,143 |
|
|
389,394 |
|
18.7 |
|
13.1 |
|
5.6 |
|
Ophthalmic Systems |
|
|
38,000 |
|
|
33,120 |
|
14.7 |
|
9.7 |
|
5.0 |
|
TOTAL |
|
$ |
1,591,400 |
|
$ |
1,405,229 |
|
13.2 |
|
7.7 |
|
5.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preanalytical Systems |
|
$ |
391,892 |
|
$ |
340,976 |
|
14.9 |
|
9.3 |
|
5.6 |
|
Diagnostic Systems |
|
|
395,985 |
|
|
351,506 |
|
12.7 |
|
7.7 |
|
5.0 |
|
TOTAL |
|
$ |
787,877 |
|
$ |
692,482 |
|
13.8 |
|
8.5 |
|
5.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Discovery Labware |
|
$ |
96,142 |
|
$ |
89,319 |
|
7.6 |
|
2.8 |
|
4.8 |
|
Immunocytometry Systems |
|
|
282,488 |
|
|
248,410 |
|
13.7 |
|
9.3 |
|
4.4 |
|
Pharmingen |
|
|
65,823 |
|
|
63,416 |
|
3.8 |
|
0.2 |
|
3.6 |
|
TOTAL |
|
$ |
444,453 |
|
$ |
401,145 |
|
10.8 |
|
6.4 |
|
4.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL INTERNATIONAL |
|
$ |
2,823,730 |
|
$ |
2,498,856 |
|
13.0 |
|
7.7 |
|
5.3 |
|
Page 11
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
|
|
Total |
|||||||||||
|
|
|
|
|
|
|
|
% Change |
|
|
|
||
|
|
2005 |
|
2004 |
|
Reported |
|
FX Neutral |
|
FX Impact |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD MEDICAL |
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical Surgical Systems |
|
$ |
1,661,150 |
|
$ |
1,540,723 |
|
7.8 |
|
5.2 |
|
2.6 |
|
Diabetes Care |
|
|
674,020 |
|
|
586,190 |
|
15.0 |
|
12.5 |
|
2.5 |
|
Pharmaceutical Systems |
|
|
563,271 |
|
|
497,421 |
|
13.2 |
|
8.8 |
|
4.4 |
|
Ophthalmic Systems |
|
|
59,647 |
|
|
55,831 |
|
6.8 |
|
3.9 |
|
2.9 |
|
TOTAL |
|
$ |
2,958,088 |
|
$ |
2,680,165 |
|
10.4 |
|
7.4 |
|
3.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD DIAGNOSTICS |
|
|
|
|
|
|
|
|
|
|
|
|
|
Preanalytical Systems |
|
$ |
854,831 |
|
$ |
787,996 |
|
8.5 |
|
6.1 |
|
2.4 |
|
Diagnostic Systems |
|
|
802,233 |
|
|
743,643 |
|
7.9 |
|
5.5 |
|
2.4 |
|
TOTAL |
|
$ |
1,657,064 |
|
$ |
1,531,639 |
|
8.2 |
|
5.8 |
|
2.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BD BIOSCIENCES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Discovery Labware |
|
$ |
206,561 |
|
$ |
190,140 |
|
8.6 |
|
6.4 |
|
2.2 |
|
Immunocytometry Systems |
|
|
452,383 |
|
|
397,151 |
|
13.9 |
|
11.1 |
|
2.8 |
|
Pharmingen |
|
|
140,585 |
|
|
135,650 |
|
3.6 |
|
2.0 |
|
1.6 |
|
TOTAL |
|
$ |
799,529 |
|
$ |
722,941 |
|
10.6 |
|
8.1 |
|
2.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL REVENUES |
|
$ |
5,414,681 |
|
$ |
4,934,745 |
|
9.7 |
|
7.0 |
|
2.7 |
|
Page 12